The Potential for Treatment of Skeletal Muscle Disorders with Adipose-Derived Stem Cells

2010 ◽  
Vol 5 (2) ◽  
pp. 133-136 ◽  
Author(s):  
Hiroshi Mizuno
Keyword(s):  
Skeletal Muscle ◽  
Stem Cells ◽  
Adipose Derived Stem Cells ◽  
Muscle Disorders ◽  
Skeletal Muscle Disorders

scholarly journals Therapeutic potential of adipose-derived stem cells and macrophages for ischemic skeletal muscle repair

2017 ◽  
Vol 12 (2) ◽  
pp. 153-167 ◽  
Author(s):  
Viktoriya Rybalko ◽  
Pei-Ling Hsieh ◽  
Laura M Ricles ◽  
Eunna Chung ◽  
Roger P Farrar ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Stem Cells ◽  
Therapeutic Potential ◽  
Adipose Derived Stem Cells ◽  
Muscle Repair

Activities of creatine kinase and its isoenzymes in serum in various skeletal muscle disorders.

1988 ◽  
Vol 34 (12) ◽  
pp. 2460-2462 ◽  
Author(s):  
J Arenas ◽  
V Diaz ◽  
G Liras ◽  
E Gutierrez ◽  
I Santos ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Creatine Kinase ◽  
Clinical Features ◽  
Principal Factor ◽  
Isoenzyme Pattern ◽  
Type I ◽  
Isoenzyme Analysis ◽  
Muscle Disorders ◽  
Total Creatine ◽  
Skeletal Muscle Disorders

Abstract We studied possible correlations between anatomopathological and clinical features and the values for total creatine kinase (CK; EC 2.7.3.2) and its isoenzymes, including the proportion of CK-MB, in a population displaying several neuromuscular pathologies. Although we observed no specific isoenzyme pattern associated with the different myopathies, we found isoenzyme analysis useful in studying the histopathological evolution of illness. We also considered whether the pathology was regenerative or nonregenerative, and what type of fiber (I or II) was involved. High CK-MB percentages (greater than 6%) were associated with regenerative and type I fiber myopathies, with regenerative type tissues being the principal factor associated with an increasing proportion of CK-MB. Studying the changes in CK-MB percentage in serum appears to be useful in discriminating neuromuscular from myocardial pathologies.

scholarly journals Is Gene-Size an Issue for the Diagnosis of Skeletal Muscle Disorders?

2020 ◽  
Vol 7 (3) ◽  
pp. 203-216 ◽  
Author(s):  
Marco Savarese ◽  
Salla Välipakka ◽  
Mridul Johari ◽  
Peter Hackman ◽  
Bjarne Udd
Keyword(s):  
Skeletal Muscle ◽  
Muscle Disorders ◽  
Gene Size ◽  
Skeletal Muscle Disorders

Gene Therapy of Skeletal Muscle Disorders Using Viral Vectors

Muscle ◽  
2012 ◽  
pp. 1045-1051 ◽  
Author(s):  
Andrea L.H. Arnett ◽  
Julian N. Ramos ◽  
Jeffrey S. Chamberlain
Keyword(s):  
Skeletal Muscle ◽  
Gene Therapy ◽  
Viral Vectors ◽  
Muscle Disorders ◽  
Skeletal Muscle Disorders

scholarly journals Impact of Melatonin on Skeletal Muscle and Exercise

Cells ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 288 ◽  
Author(s):  
Alessandra Stacchiotti ◽  
Gaia Favero ◽  
Luigi Fabrizio Rodella
Keyword(s):  
Quality Of Life ◽  
Skeletal Muscle ◽  
Human Aging ◽  
Muscle Disorders ◽  
Age Related ◽  
Anti Oxidant ◽  
Therapeutic Tools ◽  
Skeletal Muscle Disorders ◽  
Preclinical And Clinical Studies

Skeletal muscle disorders are dramatically increasing with human aging with enormous sanitary costs and impact on the quality of life. Preventive and therapeutic tools to limit onset and progression of muscle frailty include nutrition and physical training. Melatonin, the indole produced at nighttime in pineal and extra-pineal sites in mammalians, has recognized anti-aging, anti-inflammatory, and anti-oxidant properties. Mitochondria are the favorite target of melatonin, which maintains them efficiently, scavenging free radicals and reducing oxidative damage. Here, we discuss the most recent evidence of dietary melatonin efficacy in age-related skeletal muscle disorders in cellular, preclinical, and clinical studies. Furthermore, we analyze the emerging impact of melatonin on physical activity. Finally, we consider the newest evidence of the gut–muscle axis and the influence of exercise and probably melatonin on the microbiota. In our opinion, this review reinforces the relevance of melatonin as a safe nutraceutical that limits skeletal muscle frailty and prolongs physical performance.

Transforming growth factor-?2 is elevated in skeletal muscle disorders

1999 ◽  
Vol 22 (7) ◽  
pp. 889-898 ◽  
Author(s):  
Nobuyuki Murakami ◽  
Ian S. McLennan ◽  
Ikuya Nonaka ◽  
Kyoko Koishi ◽  
Christina Baker ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Growth Factor ◽  
Transforming Growth Factor ◽  
Muscle Disorders ◽  
Skeletal Muscle Disorders

scholarly journals Proteomic profiling of animal models mimicking skeletal muscle disorders

2007 ◽  
Vol 1 (9) ◽  
pp. 1169-1184 ◽  
Author(s):  
Philip Doran ◽  
Joan Gannon ◽  
Kathleen O'Connell ◽  
Kay Ohlendieck
Keyword(s):  
Skeletal Muscle ◽  
Animal Models ◽  
Proteomic Profiling ◽  
Muscle Disorders ◽  
Skeletal Muscle Disorders

scholarly journals Directed Differentiation of Human Pluripotent Stem Cells toward Skeletal Myogenic Progenitors and Their Purification Using Surface Markers

Cells ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. 2746
Author(s):  
Nasa Xu ◽  
Jianbo Wu ◽  
Jose L. Ortiz-Vitali ◽  
Yong Li ◽  
Radbod Darabi
Keyword(s):  
Skeletal Muscle ◽  
Stem Cells ◽  
Pluripotent Stem Cells ◽  
Disease Modeling ◽  
Human Pluripotent Stem Cells ◽  
Directed Differentiation ◽  
Surface Markers ◽  
Gene Correction ◽  
Muscle Disorders

Advancements in reprogramming somatic cells into induced pluripotent stem cells (iPSCs) have provided a strong framework for in vitro disease modeling, gene correction and stem cell-based regenerative medicine. In cases of skeletal muscle disorders, iPSCs can be used for the generation of skeletal muscle progenitors to study disease mechanisms, or implementation for the treatment of muscle disorders. We have recently developed an improved directed differentiation method for the derivation of skeletal myogenic progenitors from hiPSCs. This method allows for a short-term (2 weeks) and efficient skeletal myogenic induction (45–65% of the cells) in human pluripotent stem cells (ESCs/iPSCs) using small molecules to induce mesoderm and subsequently myotomal progenitors, without the need for any gene integration or modification. After initial differentiation, skeletal myogenic progenitors can be purified from unwanted cells using surface markers (CD10+CD24−). These myogenic progenitors have been extensively characterized using in vitro gene expression/differentiation profiling as well as in vivo engraftment studies in dystrophic (mdx) and muscle injury (VML) rodent models and have been proven to be able to engraft and form mature myofibers as well as seeding muscle stem cells. The current protocol describes a detailed, step-by-step guide for this method and outlines important experimental details and troubleshooting points for its application in any human pluripotent stem cells.

Sign in / Sign up

Export Citation Format

Share Document